Free Trial
ASX:ALA

Arovella Therapeutics (ALA) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
1.23%
Price Target
N/A

About Arovella Therapeutics

Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat insomnia, which is marketed under the brand name of Ambien or Stilnox; and invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.

ALA Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive ALA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arovella Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-10,230,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.97 million

Miscellaneous

Outstanding Shares
1,050,000,000
Free Float
N/A
Optionable
Not Optionable
Beta
-0.60
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

This page (ASX:ALA) was last updated on 5/22/2024 by MarketBeat.com Staff

From Our Partners